A revolutionary cancer therapy developed by Novocure is changing the treatment landscape for glioblastoma, a fast-growing and often deadly brain tumor. The company’s device, which delivers Tumor Treating Fields (TTFields), uses low-intensity, alternating electric fields to target cancer cells without the need for drugs or invasive procedures.
TTFields therapy works by disrupting the process of mitosis, the way cells divide. Glioblastoma cells, known for their rapid and uncontrolled division, are especially vulnerable to this disruption. The therapy interferes with the cancer cells’ internal structures during replication, leading to cellular dysfunction and eventual death, while largely sparing healthy brain tissue.
The device is worn on the scalp and connected to a portable power supply, allowing patients to go about daily activities with minimal interference. When used alongside standard treatment regimens such as surgery, radiation and temozolomide chemotherapy, TTFields has been shown in clinical trials to significantly extend both progression-free and overall survival rates in glioblastoma patients.
In studies, patients using the device for more than 18 hours a day had notably better outcomes, highlighting the importance of consistent use. While not a cure, the therapy offers a critical new option for patients facing limited treatment avenues.
Regulators and clinicians alike have praised TTFields for its non-invasive nature and potential to complement existing cancer therapies. Ongoing trials are also exploring its use in other hard-to-treat cancers including mesothelioma and pancreatic cancer.
Disclaimer: This article is for educational and informational purposes only. It does not replace professional medical advice, diagnosis or treatment. Patients should consult with their oncology care team to determine whether TTFields therapy is appropriate for their condition.
